Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Research & Development (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Research & Development for 6 consecutive years, with $5.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 51.61% year-over-year to $5.4 million, compared with a TTM value of $29.9 million through Sep 2025, down 25.7%, and an annual FY2024 reading of $42.2 million, down 5.88% over the prior year.
  • Research & Development was $5.4 million for Q3 2025 at Barinthus Biotherapeutics, down from $8.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $15.1 million in Q3 2023 and bottomed at $4.4 million in Q3 2021.
  • Average Research & Development over 5 years is $9.0 million, with a median of $9.7 million recorded in 2022.
  • The sharpest move saw Research & Development skyrocketed 168.16% in 2021, then crashed 51.61% in 2025.
  • Year by year, Research & Development stood at $6.9 million in 2021, then surged by 77.08% to $12.2 million in 2022, then plummeted by 47.7% to $6.4 million in 2023, then skyrocketed by 30.39% to $8.3 million in 2024, then crashed by 35.14% to $5.4 million in 2025.
  • Business Quant data shows Research & Development for BRNS at $5.4 million in Q3 2025, $8.0 million in Q2 2025, and $8.3 million in Q1 2025.